Raymond James Starts Cytokinetics (CYTK) at Outperform
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $59.53 -0.65%
Rating Summary:
18 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 13 | New: 8
Rating Summary:
18 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 13 | New: 8
Join SI Premium – FREE
Raymond James analyst Dane Leone initiates coverage on Cytokinetics (NASDAQ: CYTK) with a Outperform rating and a price target of $54.00.
For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.
Shares of Cytokinetics closed at $39.27 yesterday.
You May Also Be Interested In
- Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
- Deutsche Bank Starts Grab Holdings Inc. (GRAB) at Buy
- Cantor Fitzgerald Starts Abbvie (ABBV) at Overweight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
